Intensive lipid-lowering and CVD.

The article highlights the follow-up analysis of the trials Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL), in which researchers have continued to emphasize the benefits of a long-term intensive lipid-lowering therapy for cardiovascular disease patients.